In addition, it is still unclear whether the expression of PD-1 and PD-L1 on tumors and TICs is a key factor for the clinical prognosis of DLBCL, NOS patients treated with PD-1/PD-L1 blockade therapy. Here, PDCD1 is linked to diffuse large B-cell lymphoma.